WallStreetZenWallStreetZen

NASDAQ: GUTS
Fractyl Health Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GUTS

Based on 3 analysts offering 12 month price targets for Fractyl Health Inc

Min Forecast
$2.00+329.18%
Avg Forecast
$6.00+1,187.55%
Max Forecast
$8.00+1,616.74%

Should I buy or sell GUTS stock?

Based on 3 analysts offering ratings for Fractyl Health Inc.

Buy
Strong Buy
1 analysts 33.33%
Buy
1 analysts 33.33%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GUTS stock forecasts and price targets.

GUTS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-30
lockedlocked$00.00+00.00%2025-12-02
lockedlocked$00.00+00.00%2025-11-21Find Out Why

1 of 1

Forecast return on equity

Is GUTS forecast to generate an efficient return?

Company
-205.26%
Industry
66.31%
Market
181.06%
GUTS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GUTS forecast to generate an efficient return on assets?

Company
5.71%
Industry
31.93%
GUTS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GUTS earnings per share forecast

What is GUTS's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.70
Avg 2 year Forecast
-$0.66
Avg 3 year Forecast
-$0.38

GUTS revenue forecast

What is GUTS's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$22.8M+758,966.67%
Avg 3 year Forecast
$119.6M+3,985,900%
GUTS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GUTS revenue growth forecast

How is GUTS forecast to perform vs Biotechnology companies and vs the US market?

Company
3,170.16%
Industry
37.67%
Market
13.46%
GUTS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GUTS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GUTS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GUTS$0.47$6.00+1,187.55%Buy
OKYO$1.66$6.33+281.51%Strong Buy
IFRX$0.95$10.00+957.08%Buy
COEP$12.04N/AN/A
GRCE$4.20N/AN/A
View Top Biotech Stocks

Fractyl Health Stock Forecast FAQ

Is Fractyl Health Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: GUTS) stock is to Buy GUTS stock.

Out of 3 analysts, 1 (33.33%) are recommending GUTS as a Strong Buy, 1 (33.33%) are recommending GUTS as a Buy, 1 (33.33%) are recommending GUTS as a Hold, 0 (0%) are recommending GUTS as a Sell, and 0 (0%) are recommending GUTS as a Strong Sell.

If you're new to stock investing, here's how to buy Fractyl Health stock.

What is GUTS's earnings growth forecast for 2026-2028?

(NASDAQ: GUTS) Fractyl Health's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.

Fractyl Health's earnings in 2026 is -$122,197,000.On average, 7 Wall Street analysts forecast GUTS's earnings for 2026 to be -$96,451,877, with the lowest GUTS earnings forecast at -$118,187,125, and the highest GUTS earnings forecast at -$77,704,197. On average, 6 Wall Street analysts forecast GUTS's earnings for 2027 to be -$90,517,853, with the lowest GUTS earnings forecast at -$114,158,019, and the highest GUTS earnings forecast at -$71,948,331.

In 2028, GUTS is forecast to generate -$52,652,474 in earnings, with the lowest earnings forecast at -$81,925,166 and the highest earnings forecast at -$8,633,800.

What is GUTS's revenue growth forecast for 2026-2028?

(NASDAQ: GUTS) Fractyl Health's forecast annual revenue growth rate of 3,170.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.

Fractyl Health's revenue in 2026 is $3,000.On average, 7 Wall Street analysts forecast GUTS's revenue for 2026 to be $0, with the lowest GUTS revenue forecast at $0, and the highest GUTS revenue forecast at $0. On average, 6 Wall Street analysts forecast GUTS's revenue for 2027 to be $3,120,775,988, with the lowest GUTS revenue forecast at $0, and the highest GUTS revenue forecast at $10,274,221,667.

In 2028, GUTS is forecast to generate $16,387,774,135 in revenue, with the lowest revenue forecast at $4,243,992,218 and the highest revenue forecast at $40,866,652,008.

What is GUTS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GUTS) forecast ROA is 5.71%, which is lower than the forecast US Biotechnology industry average of 31.93%.

What is GUTS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year GUTS price target, the average GUTS price target is $6.00, with the highest GUTS stock price forecast at $8.00 and the lowest GUTS stock price forecast at $2.00.

On average, Wall Street analysts predict that Fractyl Health's share price could reach $6.00 by Jan 30, 2027. The average Fractyl Health stock price prediction forecasts a potential upside of 1,187.55% from the current GUTS share price of $0.47.

What is GUTS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GUTS) Fractyl Health's current Earnings Per Share (EPS) is -$2.30. On average, analysts forecast that GUTS's EPS will be -$0.70 for 2026, with the lowest EPS forecast at -$0.86, and the highest EPS forecast at -$0.57. On average, analysts forecast that GUTS's EPS will be -$0.66 for 2027, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.53. In 2028, GUTS's EPS is forecast to hit -$0.38 (min: -$0.60, max: -$0.06).

What is GUTS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GUTS) forecast ROE is -205.26%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.